Potential solutions for manufacture of CAR T cells in cancer immunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Potential solutions for manufacture of CAR T cells in cancer immunotherapy

Published:2022-09-05 Issue:1 Volume:13 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Blache Ulrich^ORCID,Popp Georg,Dünkel Anna,Koehl Ulrike,Fricke Stephan

Funder

Fraunhofer Organization | Fraunhofer-Institut für Zelltherapie und Immunologie

Bundesministerium für Bildung und Forschung

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary

Link

https://www.nature.com/articles/s41467-022-32866-0.pdf

Reference20 articles.

1. Westin, J. & Sehn, L. H. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood 139, 2737–2746 (2022).

2. Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer 21, 145–161 (2021).

3. Milone, M. C. et al. Engineering-enhanced CAR T cells for improved cancer therapy. Nat. Cancer 2, 780–793 (2021).

4. Upadhaya, S. et al. The clinical pipeline for cancer cell therapies. Nat. Rev. Drug Discov. 20, 503–504 (2021).

5. Ghassemi, S. et al. Rapid manufacturing of non-activated potent CAR T cells. Nat. Biomed. Eng. 6, 118–128 (2022).

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing lentiviral vector formulation conditions for efficient ex vivo transduction of primary human T cells in chimeric antigen receptor T-cell manufacturing;Cytotherapy;2024-09

2. Accelerating Accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?;Seminars in Hematology;2024-09

3. 3D Microphysiological Tumor Model for Dual-Targeting CAR T Cell Immunotherapy;2024-08-16

4. Design of a Soluble Multivalent Notch Agonist;2024-08-08

5. Intraperitoneal programming of tailored CAR macrophages via mRNA-LNP to boost cancer immunotherapy;2024-07-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3